earli
report
suggest
sever
acut
respiratori
syndrom
coronaviru
associ
coronaviru
diseas
gener
caus
mild
diseas
children
pediatr
solid
organ
transplant
recipi
gener
suscept
viral
respiratori
infect
increas
morbid
mortal
limit
report
diseas
heart
transplant
femal
underw
orthotop
heart
transplant
monthsofag
congenit
dilat
cardiomyopathi
late
posttranspl
cours
unremark
except
persist
ebstein
barr
viru
ebv
viremia
intens
immunosuppress
reduc
tacrolimu
monotherapi
first
week
march
patient
develop
product
cough
rhinorrhea
nasal
congest
afebril
symptom
shortnessofbreath
month
prior
ill
treat
febril
bronchiol
outpati
potenti
diseas
consid
commun
incid
low
time
patient
center
diseas
control
risk
factor
infect
test
wide
avail
oneweek
later
followup
telehealth
visit
perform
improv
sever
cough
remain
afebril
surveil
laboratori
studi
includ
complet
blood
count
ebv
whole
blood
dna
antihuman
leukocyt
antigen
antibodi
test
luminex
assay
happen
perform
time
defer
patient
eventu
discharg
repeat
nasal
pcr
plan
two
week
repeat
anti
hla
antibodi
test
ivig
administr
repeat
everi
month
two
month
patient
notabl
receiv
tacrolimu
monotherapi
time
infect
due
persist
ebv
viremia
therefor
may
mount
effici
immun
respons
addit
receiv
antimetabolit
corticosteroid
vitro
data
suggest
inhibit
viral
replic
human
coronavirus
interestingli
de
novo
donor
specif
class
ii
antibodi
also
detect
infect
allosensit
follow
viral
infect
describ
due
reduc
amount
immunosuppress
patient
may
prone
phenomenon
patient
toler
ivig
administr
concurr
infect
without
notabl
reaction
would
hesit
attempt
aggress
form
desensit
activ
infect
clinic
knowledg
infect
avail
although
mechan
relationship
allosensit
remain
uncertain
suggest
care
measur
donor
specif
antibodi
undertaken
heart
transplant
survivor
infect
disclosur
author
disclosur
report
